ClinicalTrials.gg
RecruitingNCT06638385SPACE SHIELDUpdated Jul 9, 2025

A Space-expanding Shield in Decompressive Hemicraniectomy for Stroke

An interventional study of DCE + SPACE SHIELD and DCE + CP in Stroke, sponsored by Insel Gruppe AG, University Hospital Bern. Recruiting at 6 sites in Switzerland. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2025-07-09.

Sponsored by Insel Gruppe AG, University Hospital Bern · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jun 2025; still recruiting 1 year 5 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
110
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern — 7 open to participants now, 7 under way, 1 of them phase 3. Stroke · Insel Gruppe AG, University Hospital Bern.

Started
2025
with 1 other
No phase
6 of 19
2 open now
Registered
18th of 19
by date

Among the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern, this one is one of 2 that started in 2025, is one of 6 with no phase, and was the 18th registered.

Stroke

8,283 studies on the registry are indexed under Stroke; 2,065 are open to participants now.

Browse Stroke studies →

Open to participants now

7 of the 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern are open now, in 12 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 1,418 Stroke studies recruiting now, 698 (49%) set no upper age limit and 281 (20%) stop at 75 or younger; 77 take children under 18; 197 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 19 studies in Stroke by Insel Gruppe AG, University Hospital Bern, or all of them as a file.
02

Study summary

Instead of the standard decompressive hemicraniectomy with subsequent cranioplasty a single surgery with the implantation of an individually molded space-expanding shield is investigated in for patients with increased intracranial pressure due to a malignant stroke.

Read the detailed description

Background:

A malignant cerebral infarction causes edema resulting in a threatening increase of the intracranial pressure (ICP). Standard of care is a surgical removal of a part of the skull above the ischemic brain, the so-called decompressive hemicraniectomy (DCE). DCE allows the brain to swell, after detumescence of the brain parenchyma (usually several months later) the patients undergo a second surgery with implantation of either their own preserved bone flap or a bone flap substitute (a procedure referred to as cranioplasty (CP)).

Objective:

Despite its proven life-saving benefits, the strategy of DCE followed by CP carries several risks, among others

  • Exposure of the brain parenchyma
  • Various neurological deficits subsumed under the syndrome of the trephined
  • Bone resorption: As shown in a previous prospective cohort study the above-mentioned risks may be prevented using an intraoperatively molded space-expanding protective shield, which is implanted and fixed directly after having performed (a so far customary) DCE. This shield allows the brain to swell while still providing protection.

SPACE SHIELD investigates whether the single-stage strategy of implanting a space-expanding shield represents a viable alternative to the standard DCE followed by CP."

Methods:

The inclusion of patients is planned to take place from January 2025 to December 2029. The study duration for the individual patients is 6 months. While the intervention group will be treated with the above-described space-expanding shield the control group will be treated with the customary DCE and following CP. The CP will be performed either with the original bone flap stored in customary manner or with a PMME bone flap. Examinations of the patients are planned after 1 - 7 days, 6 weeks, 3 months and 6 months after the initial surgery.

03

Conditions studied

  • Stroke

Browse trials for

Keywords

  • stroke
  • bone flap
  • cranioplasty
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with malignant infarction of the middle cerebral artery identified by MRI including diffusion-weighted imaging or CT including perfusion imaging - fulfilling the European guidelines for decompressive hemicraniectomy (DCE) for stroke
  • ≥ 18 and \< 70 years of age
  • Availability of consent from a next of kin and from the patient represented by an independent physician

Exclusion criteria

Exclusion Criteria:

  • Hyperacute need for DCE due to rapid neurological decline
  • to the use of polymethyl-methacrylate (PMMA), e.g., known , allergy
  • Known gentamicin allergy
  • Pregnancy and active breast-feeding
  • Patients with a former history of DCE and/or CP
  • Active pulmonary or cranial infection
  • Known coagulopathy independent of medication
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
110 participants (estimated)

Study arms

  • Experimental
    DCE + SPACE SHIELD

    Patients in the experimental group receive a DCE with implantation of a space-expanding shield.

    Procedure: DCE + SPACE SHIELD

  • Active comparator
    DCE + CP

    Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.

    Procedure: DCE + CP

Interventions

  • ProcedureDCE + SPACE SHIELD

    Patients receive a DCE with implantation of a space-expanding shield.

  • ProcedureDCE + CP

    Patients in the control group receive a DCE similar to the intervention group, but without implantation of a space-expanding shield. Cranioplasty (CP) is performed after \~ 90 days in the customary manner.

06

What researchers measure

Primary outcomes

  1. modified Ranking Scale (mRS) score at 6 months

    The primary outcome will be assessed by a blinded, independent, local study nurse. The sole task of this study nurse will be to assess the mRS based on a short interview with the patient.

    Time frame: 6 months after surgery

Secondary outcomes

  1. Number of further surgical interventions for ICP control

    This includes surgical removal and exchange of the space-expanding shield, implantation of an EVD), surgery for further bony decompression, surgery for removal of hemorrhages or hygroma.

    Time frame: 6 months after surgery

  2. Occurrence of Hydrocephalus

    Any radiological diagnosis of hydrocephalus requiring either a shunting procedure or an EVD, including revision, at least 2 weeks after study inclusion. Procedures before 2 weeks will qualify as an intervention for ICP control (a. Further surgical interventions for ICP control)

    Time frame: 6 months after surgery

  3. Number of Infections

    Any infection leading to surgical revision and identification of bacteria by bacterial growth in microbacterial analysis from surgically obtained specimen. Wound healing difficulties treated with local treatment only (no surgical revision) will not count as infections.

    Time frame: 6 months after surgery

  4. Wound healing difficulties

    Any surgery under general anaesthesia for wound healing difficulties, unless qualified as infection. The total number of events will be reported as well as the rate of patients with at least one event.

    Time frame: 6 months after surgery

  5. Syndrome of the trephined

    The syndrome of the trephined subsumes various new or worsened neurological deficits attributed to the trephined state: headache, dizziness, fatigue, cognitive decline, decreased consciousness, sensory deficits, motor deficits, speech difficulties. It will be reported on the rate of patients experiencing the syndrome of the trephined, as well as to whether the patient's symptoms recovered following bone-flap re-insertion (fully, partially or not).

    Time frame: 6 months after surgery

  6. Overall survival at 6 months

    Time frame: 6 months after surgery

  7. Cosmetic satisfaction at 6 months

    The patient will be asked to self-evaluate the overall cosmetic results of the scar, shape of head and visible craniotomy edge using a 5-points Likert scale (very poor - poor - average - good - very good)

    Time frame: 6 months after surgery

  8. Quality of life score: EQ-5D-5L

    EuroQoL 5D-5L questionnaire (Mobility, Self-Care, Usual Activities, Pain/Discomfort, Anxiety/ Depression (rating from no problems to extreme problems) and health status self rating by patient (Score 0-100, 0 the worst health and 100 the best health))

    Time frame: 6 months after surgery

07

Study locations

6 of 6 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jun 2025 (actual). Primary completion is estimated for Dec 2029, 54 months after the start.

Of 3,121 non-industry interventional studies with no phase under Stroke, half reached primary completion within 23 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 46. This study's planned 54 months is above that.

Counting every sponsor, half of 3,265 studies reached it within 23 months; a quarter within 10 and three quarters within 46.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 9, 2024
First posted
Oct 15, 2024
StartActual
Jun 1, 2025
Primary completionEst.
Dec 31, 2029
CompletionEst.
Jun 30, 2030
Last update
Jul 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06638385
Responsible party
Sponsor
First posted
Oct 15, 2024
Start date
Jun 1, 2025
Primary completion
Dec 31, 2029 (estimated)
Completion
Jun 30, 2030 (estimated)
Last update
Jul 9, 2025

Study contacts

Philippe Schucht, MD
Contact
philippe.schucht@insel.ch
+41316322409
Kissling Cédric, MD
Contact
space@insel.ch
+41316322409
Schucht Philippe, MD
principal investigator · Inselspital Bern, Department of Neurosurgery

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion